Clinical Cancer Research Grants Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 14, 347, January 15, 2008. doi: 10.1158/1078-0432.CCR-07-0493
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prabhakar, B. S.
Right arrow Articles by Prasad, K. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prabhakar, B. S.
Right arrow Articles by Prasad, K. V.

Molecular Pathways

Role of IG20 Splice Variants in TRAIL Resistance

Bellur S. Prabhakar, Nirupama Mulherkar and Kanteti V. Prasad

Authors' Affiliation: Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, Illinois

Requests for reprints: Bellur S. Prabhakar, Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, 835 South Wolcott Street (MC 790), Chicago, IL 60612. Phone: 312-996-4945; Fax: 312-996-6415; E-mail: bprabhak{at}uic.edu.

Abstract

Tumor necrosis factor receptor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis primarily in cancer cells with little or no effect on normal cells; therefore, it has the potential for use in cancer therapy. TRAIL binding to death receptors DR4 and DR5 triggers the death-inducing signal complex formation and activation of procaspase-8, which in turn activates caspase-3, leading to cell death. Like FasL, TRAIL can trigger type 1 (caspase-8 -> caspase-3) or type 2 (caspase-8 -> Bid cleavage -> capsase-9 -> caspase-3) apoptotic pathways depending on the cell type. Some cancers are resistant to TRAIL treatment because most molecules in the TRAIL signaling pathway, including FLIPs and IAPs, can contribute to resistance. In addition, we have identified an essential role for splice variants of the IG20 gene in TRAIL resistance.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
M. Subramanian, T. Pilli, P. Bhattacharya, F. Pacini, Y. E. Nikiforov, P. V. Kanteti, and B. S. Prabhakar
Knockdown of IG20 Gene Expression Renders Thyroid Cancer Cells Susceptible to Apoptosis
J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1467 - 1471.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. C. Li, J. R. Sheng, N. Mulherkar, B. S. Prabhakar, and M. N. Meriggioli
Regulation of Apoptosis and Caspase-8 Expression in Neuroblastoma Cells by Isoforms of the IG20 Gene
Cancer Res., September 15, 2008; 68(18): 7352 - 7361.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.